Amicus Therapeutics, Inc. Sued for Securities Fraud In An Expanded Class Period

BOSTON, Oct. 8, 2015

The lawsuit charges that Amicus and certain of its officers misrepresented when it would be able to file its New Drug Application with the Food and Drug Administration ("FDA") for its NDA for its oral small molecule pharmacological chaperone migalastat for the treatment of Fabry disease.  Defendants publicly stated that, based on information provided by the FDA, the NDA was on track for filing in the fourth quarter of 2015. 

On October 2, 2015, Amicus revealed that it would no longer be in a position to submit its NDA in the fourth quarter of 2015.  Amicus' stock price plunged on this news, falling by 54% to $6.39 per share.

If you purchased Amicus stock between March 19, 2015 and October 1, 2015 you may be a member of the alleged class.  You may move the Court to be a lead plaintiff or you need not take any action at this time.  If you wish to be a lead plaintiff, you must file a motion by December 7, 2015.  If you are interested in becoming a lead plaintiff, have questions about your legal rights, or if you have information relevant to this investigation, please contact attorneys Jake Walker or Jeffrey Block of Block & Leviton LLP at (617) 398-5600 or at Jake@blockesq.com or Jeff@blockesq.com.  You may also retain counsel of your own choosing.  Confidentiality for any whistleblowers or other persons with information relevant to the investigation is assured.

Block & Leviton represents investors for violations of securities laws as well as whistleblowing employees who provide information about their employers' violations of law throughout the country.  The firm's lawyers have collectively been prosecuting securities cases for over 70 years, have recovered billions of dollars for investors and represent some of the nation's largest institutional investors.

This notice may constitute attorney advertising. 

Contact:         
BLOCK & LEVITON LLP
Jake Walker Jake@blockesq.com
Jeffrey Block Jeff@blockesq.com
(617) 398-5600